Trials / NCT05355415
Adaptive Optics Imaging of Outer Retinal Diseases
Recruiting now Observational Natural history / observational
- Sponsor
- Food and Drug Administration (FDA)
- Treatment
- Adaptive optics imaging
- Gene
- Not stated
- Conditions
- Retinal Degeneration, Age-Related Macular Degeneration, Retinitis Pigmentosa, Hydroxychloroquine Retinopathy, Usher Syndromes, Late-Onset Retinal Degeneration, Cone Dystrophy, Cone Rod Dystrophy, Rod Cone Dystrophy, Rod Dystrophy
- Ages
- 21 Years to no upper limit
- Enrollment
- 100 participants
- Started
- 2021-08-27
- Main results expected
- 2028-09-30
- Results posted
- Not yet
- Record last updated
- 2026-05-08
What the study is testing
The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.
Where it runs
United States (2)
- NIH Clinical Center, Bethesda, Maryland (recruiting now)
- Food and Drug Administration, Silver Spring, Maryland (recruiting now)